Ionis Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$40.15

−0.67%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $41.38
Previous close: $40.42
Volume: 4.1M
Day's high: $41.53
Day's low: $39.33

In brief

Ionis Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $6.67B.
Its shares closed at $40.15 on 4 Nov 2026, down 44.9% over the past year.
From India you can buy IONS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Ionis Pharmaceuticals, Inc. (IONS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IONS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IONS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Set a 52-week low on 4 Nov 2026
Closed at $40.15 on 4 Nov 2026: 53.7% below the 52-week high of $86.74 (8 Jul 2026) and 2.1% above the low of $39.33 (4 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −8.8% (SPY −1.6%, XLV +13.5%). 3 months: −25.9% (SPY −0.4%, XLV +15.5%). 1 year: −44.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IONS, SPY and XLV · as of 4 Nov 2026
7.7 days to cover short interest
20.7M shares were sold short at the 15 Oct 2026 settlement, 12.4% of the 166.2M shares outstanding; covering them would take 7.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $40.15 was 15.9% below its 50-day average ($47.75) and 39.4% below its 200-day average ($66.24). It has closed below the 200-day for 84 sessions, since 9 Jul 2026. The 50-day average crossed below the 200-day on 17 Jun 2026, 97 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−8.8%

6 months−47.8%

1 year−44.9%

5 years+15.9%

Newswire

About

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Website

Notable moves

July 9, 2026
−23.90%
September 2, 2025
+34.84%
May 9, 2022
−12.64%

Newswire

About

Website

Notable moves

July 9, 2026
−23.90%
September 2, 2025
+34.84%
May 9, 2022
−12.64%

Ionis Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$40.15

−0.67%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $41.38
Previous close: $40.42
Volume: 4.1M
Day's high: $41.53
Day's low: $39.33

In brief

Ionis Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $6.67B.
Its shares closed at $40.15 on 4 Nov 2026, down 44.9% over the past year.
From India you can buy IONS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Ionis Pharmaceuticals, Inc. (IONS) shares from India?

Do I need the price of a whole IONS share to invest?

How much can I invest in US stocks in a year?

Can I trade IONS options or futures?

Insights

Quotes run fifteen minutes behind.

Set a 52-week low on 4 Nov 2026
Closed at $40.15 on 4 Nov 2026: 53.7% below the 52-week high of $86.74 (8 Jul 2026) and 2.1% above the low of $39.33 (4 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −8.8% (SPY −1.6%, XLV +13.5%). 3 months: −25.9% (SPY −0.4%, XLV +15.5%). 1 year: −44.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IONS, SPY and XLV · as of 4 Nov 2026
7.7 days to cover short interest
20.7M shares were sold short at the 15 Oct 2026 settlement, 12.4% of the 166.2M shares outstanding; covering them would take 7.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $40.15 was 15.9% below its 50-day average ($47.75) and 39.4% below its 200-day average ($66.24). It has closed below the 200-day for 84 sessions, since 9 Jul 2026. The 50-day average crossed below the 200-day on 17 Jun 2026, 97 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−8.8%

6 months−47.8%

1 year−44.9%

5 years+15.9%

Newswire

About

Website

Notable moves

July 9, 2026
−23.90%
September 2, 2025
+34.84%
May 9, 2022
−12.64%

Newswire

About

Website

Notable moves

July 9, 2026
−23.90%
September 2, 2025
+34.84%
May 9, 2022
−12.64%

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. in brief

Set a 52-week low on 4 Nov 2026

Behind SPY and its sector fund XLV over 1 year

7.7 days to cover short interest

Below its 50- and 200-day averages

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. in brief

Set a 52-week low on 4 Nov 2026

Behind SPY and its sector fund XLV over 1 year

7.7 days to cover short interest

Below its 50- and 200-day averages